Figure 1.
P. vivax life cycle and sites of action for different antimalarials.
Figure 2.
Possible sources of residual blood parasitemia after initial treatment and possible genetic similarity or dissimiliarity.
Table 1.
Parasite and fever clearance times in patients treated with artemether or AL for P. vivax.
Table 2.
Parasitological failure in patients treated with AL for P. vivax.
Table 3.
Appearance of new P. vivax infections in patients with P. falciparum monoinfection at the time of treatment.